Zars Pharma (MM) (ZARS)

ZARS Pharma, Inc. manufactures and commercializes topically administered drugs primarily in the area of pain management. Its products include Pliaglis, a topical local anesthetic cream that provides local dermal anesthesia on intact skin prior to painful cosmetic procedures, such as dermatologic las... ZARS Pharma, Inc. manufactures and commercializes topically administered drugs primarily in the area of pain management. Its products include Pliaglis, a topical local anesthetic cream that provides local dermal anesthesia on intact skin prior to painful cosmetic procedures, such as dermatologic laser surgery and dermal filler injections; Synera, a topical patch designed to provide local dermal anesthesia for potentially painful superficial procedures, which includes venous access procedures involving needles and immunization injections of children; and Flexicaine, which is designed to provide rapid dermal analgesia to affected skin for the treatment of post-herpetic neuralgia. The company’s products also comprise Steroid DuraPeel, a phase-changing gel designed to deliver a steroid locally for an extended period of time for the treatment of corticosteroid-responsive dermatoses, including hand dermatitis and psoriasis; Alprazolam Patch, which is used for treating general anxiety and panic disorders; and Risperidone Patch, which delivers risperidone across the skin at a controlled rate for up to three days. ZARS Pharma, Inc. was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July 2007. The company was founded in 1996 and is based in Salt Lake City, Utah. As of May 12, 2011, ZARS Pharma, Inc. operates as a subsidiary of Nuvo Pharmaceuticals Inc. 詳細を表示